Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

All doses of the weight loss drugs are listed as "available" by the FDA. After years of ongoing shortages due to their ...

It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

Renowned plant-based physician Dr. Michael Greger has released a new book on the risks, benefits, and alternatives to Ozempic ...

Both Ozempic and Wegovy are forms of semaglutide, a GLP-1 agonist drug manufactured by Novo Nordisk. When reached for comment ...

Ozempic, Wegovy considered ‘available’ after more than 2 years in shortage - Demand for the popular weight loss and diabetes ...

You may have heard about — or maybe even experienced — the short-term side effects of Ozempic® — such as nausea, vomiting, ...

Previously, the lowest dose of Wegovy, 25 milligrams, was listed as in short supply. Since early 2022, several doses of semaglutide — the active ingredient in Wegovy and Ozempic — had been on the ...

The high price and side effects of Ozempic, the blockbuster diabetes drug also used off label for weight loss, has led people ...

Beverly Tchang, MD, an endocrinologist and obesity specialist at Weill Cornell Medicine in New York City, instructs some of ...